MaxCyte, Inc. (LON:MXCT – Get Free Report)’s share price fell 0.8% during trading on Friday . The stock traded as low as GBX 1.26 and last traded at GBX 1.28. 1,239,267 shares changed hands during mid-day trading, an increase of 2,846% from the average session volume of 42,065 shares. The stock had previously closed at GBX 1.29.
MaxCyte Price Performance
The company has a quick ratio of 14.38, a current ratio of 12.39 and a debt-to-equity ratio of 9.70. The firm has a fifty day moving average price of GBX 1.11 and a two-hundred day moving average price of GBX 1.03. The stock has a market capitalization of £1.36 million, a P/E ratio of -0.03 and a beta of 1.13.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
See Also
- Five stocks we like better than MaxCyte
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
